Adjusted outcomes for DLBCL patients undergoing auto-HCT in PR who received ≥2 prior lines of chemotherapy
| Outcomes . | No ECF (n = 64) . | ECF (n = 150) . | P . |
|---|---|---|---|
| NRM | |||
| 1-y | 3.2 (0.06-9.9) | 7.3 (3.9-12.3) | .18 |
| 3-y | 8.4 (3-17.3) | 10.3 (6-16) | .66 |
| 5-y | 8.4 (3-17.3) | 11.6 (6.8-17.7) | .49 |
| Progression or relapse | |||
| 1-y | 33.3 (21.9-45.1) | 41.4 (33.4-49.2) | .26 |
| 3-y | 50.8 (37.3-62.7) | 45.1 (36.9-53) | .47 |
| 5-y | 56.5 (41.7-68.9) | 49.5 (40.7-57.7) | .40 |
| PFS | |||
| 1-y | 67.2 (56.2-78.2) | 49.9 (42-57.7) | .01 |
| 3-y | 46.6 (34.6-58.7) | 43.1 (35.3-50.9) | .63 |
| 5-y | 41.5 (28.7-54.2) | 37.5 (29.4-45.6) | .61 |
| OS | |||
| 1-y | 84.6 (76.2-92.9) | 63.2 (55.5-70.8) | <.001 |
| 3-y | 69.1 (58.2-80.1) | 51.9 (43.9-59.8) | .01 |
| 5-y | 61.6 (49.6-73.6) | 48.4 (40.2-56.7) | .08 |
| Outcomes . | No ECF (n = 64) . | ECF (n = 150) . | P . |
|---|---|---|---|
| NRM | |||
| 1-y | 3.2 (0.06-9.9) | 7.3 (3.9-12.3) | .18 |
| 3-y | 8.4 (3-17.3) | 10.3 (6-16) | .66 |
| 5-y | 8.4 (3-17.3) | 11.6 (6.8-17.7) | .49 |
| Progression or relapse | |||
| 1-y | 33.3 (21.9-45.1) | 41.4 (33.4-49.2) | .26 |
| 3-y | 50.8 (37.3-62.7) | 45.1 (36.9-53) | .47 |
| 5-y | 56.5 (41.7-68.9) | 49.5 (40.7-57.7) | .40 |
| PFS | |||
| 1-y | 67.2 (56.2-78.2) | 49.9 (42-57.7) | .01 |
| 3-y | 46.6 (34.6-58.7) | 43.1 (35.3-50.9) | .63 |
| 5-y | 41.5 (28.7-54.2) | 37.5 (29.4-45.6) | .61 |
| OS | |||
| 1-y | 84.6 (76.2-92.9) | 63.2 (55.5-70.8) | <.001 |
| 3-y | 69.1 (58.2-80.1) | 51.9 (43.9-59.8) | .01 |
| 5-y | 61.6 (49.6-73.6) | 48.4 (40.2-56.7) | .08 |
Data are percentage probability (95% CI). Bold values are statistically significant P values.